[Federal Register Volume 75, Number 248 (Tuesday, December 28, 2010)]
[Notices]
[Pages 81625-81626]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-32629]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of Federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Hesperetin Therapy for Metabolic Syndrome and Insulin Resistance
Description of Technology: Hesperidin is a flavonoid compound found
in citrus fruits. Large epidemiological studies have linked increased
consumption of flavonoid-rich foods, such as citrus, with reduced
cardiovascular morbidity and mortality. Investigators from the National
Center for Complementary and Alternative Medicine have demonstrated
that administration of oral hesperidin to patients with metabolic
syndrome attenuates biomarkers of inflammation and improves blood
vessel relaxation, lipid cholesterol profiles, and insulin sensitivity
when compared to controls. Thus, hesperidin and its active aglycone
form, hesperetin, may be effective agents for the treatment of
diabetes, obesity, metabolic syndrome, dyslipidemias, and their
cardiovascular complications including hypertension, atherosclerosis,
coronary heart disease, and stroke. This technology discloses methods
for using a hesperetin composition to treat metabolic syndrome and
insulin resistance.
Applications: Therapeutics for metabolic syndrome and insulin
resistance.
Development Status: Clinical trial data available.
Inventors: Michael J. Quon and Ranganath Muniyappa (NCCAM).
Publications: Manuscript in preparation.
Patent Status: U.S. Provisional Application No. 61/369,229 filled
30 July 2010 (HHS Reference No. E-148-2010/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Tara L. Kirby, Ph.D.; 301-435-4426;
[email protected].
Substituted Triazine and Purine Compounds for the Treatment of Chagas
Disease and African Trypanosomiasis
Description of Technology: Parasitic protozoa are responsible for a
wide variety of infections in both humans and animals. Trypanosomiasis
poses health risks to millions of people across multiple countries in
Africa and North and South America. Visitors to these regions, such as
business travelers and tourists, are also at risk for contracting
parasitic diseases. There are two types of African trypanosomiasis,
also known as sleeping sickness. One type is caused by the parasite
Trypanosoma brucei gambiense, and the other is caused by the parasite
Trypanosoma brucei rhodesiensi. If left untreated, African sleeping
sickness results in death. Chagas disease, caused by Trypanosoma cruzi
(T. cruzi), affects millions of people in Mexico and South and Central
America. Untreated, Chagas disease causes decreased life expectancy and
can also result in death.
The subject invention covers novel triazine and purine compounds
that are inhibitors of key proteases (cruzain and Rhodesian) of the
parasites Trypanosoma brucei rhodesiensi and Trypanosoma cruzi,
respectively.
Applications: Prophylactic and therapeutic treatment of African
trypanosomiasis and Chagas disease.
Advantages
Novel compounds against the cysteine proteases, cruzain
and rhodesain.
Compounds possess low nanomolar inhibitory potential
against cruzain and rhodesain.
Development Status: In vitro and in vivo data are available upon
request and upon execution of an appropriate confidentiality agreement.
Inventors: Craig J. Thomas et al. (NHGRI).
Related Publication: BT Mott et al. Identification and optimization
of inhibitors of Trypanosomal cysteine
[[Page 81626]]
proteases: cruzain, rhodesain, and TbCatB. J Med Chem. 2010 Jan
14;53(1):52-60. [PubMed: 19908842]
Patent Status: PCT Application No. PCT/US2009/063078 filed 03 Nov
2009, which published as WO 2010/059418 on 27 May 2010 (HHS Reference
No. E-267-2008/0-PCT-02)
Licensing Status: Available for licensing.
Licensing Contact: Kevin W. Chang, Ph.D.; 301-435-5018;
[email protected].
Collaborative Research Opportunity: The NIH Chemical Genomics
Center (NCGC) is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize appropriate lead compounds described in the
patent application. Please contact Dr. Craig J. Thomas
([email protected]) or Claire Driscoll ([email protected]),
Director of the NHGRI Technology Transfer Office, for more information.
A Novel, Inhibitory Platelet Surface Protein (TREM Like Transcript,
TLT-1): New Target for the Treatment of Cancer, Infectious Diseases,
Cardiac Diseases, and Platelet-Associated Disorders
Description of Technology: Triggering Receptors in Myeloid Cells
(TREM) recently were discovered to modulate innate and adaptive
immunity. Specifically, TREM1 amplifies the response to sepsis in
innate immunity by activating neutrophils and other leukocytes; and
TREM2 potentiates dendritic cell maturation in adaptive immunity.
This invention describes a novel, inhibitory platelet surface
protein known as TREM like Transcript (TLT-1). TLT-1 is the first
inhibitory receptor discovered to reside within the TREM gene locus.
Structurally, TLT-1 also possesses inhibitory domains that indicate
this regulatory function. TLT-1 is highly expressed in peripheral blood
platelets and may modulate many other types of myeloid cells.
Additionally, the invention describes specific, human, single chain
antibodies (scFvs) that recognize TLT-1.
Applications
This discovery implies the receptor has an important
regulatory role in both innate and adaptive immunity.
TLT-1 is a potential therapeutic target for thrombosis and
other platelet-associated disorders, as well as immune disorders,
cancer, septic shock, infectious disease, stroke, heart disease,
myocardial infarction, vascular disorders.
Detection of soluble TLT-1 in patient plasma suggests the
protein is a marker of ongoing coagulopathies.
Defective platelet aggregation in TLT-1 null mice confirms
a role for the protein in regulation of thrombosis associated with
inflammation.
Advantages
In vitro proof of concept data available--Three of the
anti-TLT-1 scFvs inhibit thrombin-induced aggregation of human
platelets in a dose-dependent manner.
Complete human origin of these antibodies suggests
negligible immunogenicity and minimizes the problem of adverse immune
responses in human therapy.
Target validation is complete. TLT-1 null mice demonstrate
defects in platelet aggregation with no gross bleeding defect.
Development Status: In vitro experiments completed. Target
validation with null mice completed. In vivo animal studies with scFv
are currently ongoing.
Inventors: Toshiyuki Mori et al. (NCI)
Related Publication: Giomarelli B, Washington VA, Chisholm MM,
Quigley L, McMahon JB, Mori T, McVicar DW. Inhibition of thrombin-
induced platelet aggregation using human single-chain Fv antibodies
specific for TREM-like transcript-1. Thromb Haemost. 2007
Jun;97(6):955-963. [PubMed: 17549298]
Patent Status: U.S. Patent No. 7,553,936 issued on 30 Jun 2009 (HHS
Reference No. E-177-2006/0-US-01)
Licensing Status: Available for licensing.
Licensing Contact: Betty B. Tong, PhD; 301-594-6565;
[email protected].
Collaborative Research Opportunity: The National Cancer Institute's
Molecular Targets Development Program is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize antibodies that
react specifically with TLT-1. Please contact John D. Hewes, PhD at
301-435-3121 or [email protected] for more information.
Dated: December 21, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-32629 Filed 12-27-10; 8:45 am]
BILLING CODE 4140-01-P